Display options
Share it on

P T. 2013 Aug;38(8):484-8.

Clinical outcomes after conversion from brand-name tacrolimus (prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study.

P & T : a peer-reviewed journal for formulary management

Kwaku Marfo, Samuel Aitken, Enver Akalin

PMID: 24222980 PMCID: PMC3814440

Abstract

After kidney transplant recipients who received Prograf were switched to generic tacrolimus, most differences in the safety and effectiveness of the medications were not considered clinically relevant.

References

  1. Health Serv Res. 2003 Aug;38(4):1051-63 - PubMed
  2. Pharmacotherapy. 2012 Nov;32(11):981-7 - PubMed
  3. Clin Transplant. 2006 May-Jun;20(3):313-7 - PubMed
  4. Am J Transplant. 2012 Oct;12(10):2825-31 - PubMed
  5. Transplant Proc. 2008 Sep;40(7):2237-9 - PubMed
  6. Transplant Proc. 2003 Jun;35(4):1308-13 - PubMed
  7. Ann Pharmacother. 2009 Oct;43(10):1583-97 - PubMed
  8. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155 - PubMed
  9. JAMA. 1987 Sep 4;258(9):1200-4 - PubMed
  10. Transplantation. 1997 Aug 15;64(3):436-43 - PubMed
  11. Ann Intern Med. 2005 Jun 7;142(11):891-7 - PubMed
  12. Am J Transplant. 2011 Sep;11(9):1861-7 - PubMed
  13. Clin Pharmacokinet. 1995 Dec;29(6):404-30 - PubMed
  14. Transplantation. 2005 Dec 15;80(11):1633-5 - PubMed
  15. Transplantation. 2011 Sep 27;92(6):653-7 - PubMed
  16. BMJ. 1999 Apr 24;318(7191):1104-7 - PubMed
  17. Am J Kidney Dis. 1999 Feb;33(2):389-97 - PubMed
  18. Transplant Proc. 2008 Apr;40(3):705-7 - PubMed

Publication Types